📰 Respivant Sciences News
Respivant Sciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Respivant Sciences. Real-time updates on events, politics, business and more.
May 15, 2023
Heidi Henson was appointed to the Board of Directors and named Audit Committee Chair taking over from Rob Williamson, III, who will continue to serve as a...
May 15, 2023
Heidi Henson was appointed to the Board of Directors and named Audit Committee Chair taking over from Rob Williamson, III, who will continue to serve as a member of the CommitteeMichael McCormick... | May 15, 2023
February 25, 2022
/PRNewswire/ -- The "Global Idiopathic Pulmonary Fibrosis Market, By Therapy, Estimation & Forecast, 2017-2030" report has been added to...
February 25, 2022
/PRNewswire/ -- The "Global Idiopathic Pulmonary Fibrosis Market, By Therapy, Estimation & Forecast, 2017-2030" report has been added to...
January 28, 2021
Esbriet, and Ofev (tyrosine kinase inhibitors). Both drugs have been shown to slow the disease progression but do not significantly impact mortality. The surge in Idiopathic Pulmonary Fibrosis market size is due to an increase in the prevalence of IPF patients in the 7MM, along with promising assets such as RG 6354, Pamrevlumab, Of all the emerging therapies, the most anticipated product to launch is the RG 6354 (Roche). It has received Breakthrough Therapy Designation from the FDA. Apart ...